CD274 and head and neck squamous cell carcinoma: Only the EGFR inhibitor cetuximab and the PD-1/PD-L1 immune checkpoint inhibitors pembrolizumab, nivolumab, and durvalumab, improve survival in recurrent or metastatic HNSCC [51].